Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 12,394 Shares

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Sullivan sold 12,394 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total value of $202,394.02. Following the completion of the transaction, the chief financial officer directly owned 39,900 shares in the company, valued at approximately $651,567. The trade was a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, September 10th, Christopher Sullivan sold 10,185 shares of Avalo Therapeutics stock. The shares were sold at an average price of $17.62, for a total value of $179,459.70.

Avalo Therapeutics Trading Down 0.7%

Shares of AVTX stock traded down $0.12 during mid-day trading on Friday, reaching $16.57. The stock had a trading volume of 3,233,361 shares, compared to its average volume of 1,154,871. The business’s fifty day moving average is $18.81 and its 200-day moving average is $17.05. The firm has a market cap of $888.65 million, a price-to-earnings ratio of -3.79 and a beta of 0.78. Avalo Therapeutics, Inc. has a 1-year low of $10.70 and a 1-year high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, analysts forecast that Avalo Therapeutics, Inc. will post -2.69 earnings per share for the current year.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Braidwell LP acquired a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at about $30,107,000. Seven Fleet Capital Management LP raised its holdings in Avalo Therapeutics by 806.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock worth $8,568,000 after purchasing an additional 510,540 shares during the period. Squarepoint Ops LLC raised its holdings in Avalo Therapeutics by 624.9% in the 2nd quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after purchasing an additional 507,960 shares during the period. DV Trading LLC purchased a new position in Avalo Therapeutics during the first quarter worth approximately $5,376,000. Finally, Affinity Asset Advisors LLC boosted its position in Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after purchasing an additional 289,786 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on AVTX shares. Weiss Ratings upgraded shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Leerink Partners began coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They set an “outperform” rating and a $38.00 target price for the company. Bank of America initiated coverage on shares of Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, HC Wainwright cut their price target on Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $45.10.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research strategy centers on treatments intended to address conditions in which abnormal immune system activity contributes to disease progression.

Avalo’s lead product candidate is AVTX-009, an investigational fully human monoclonal antibody designed to inhibit interleukin-1 beta (IL-1?), a signaling protein involved in inflammation.